This proposition was validated when we generated two KRAS G12C inhibitor–resistant cancer cell lines from KRAS G12C–mutant parental cells (MiaPaCa-2) and found that both AMG510- and MRTX1257-resistant cell lines were indeed sensitive to the XPO1 inhibitor selinexor. This evidence concerns the gene XPO1 and cancer.